Data / Form D filings / ALLOZYNE INC
ALLOZYNE INC: Form D filings
ALLOZYNE INC, a biotechnology company in Seattle, WA, filed 5 Form D notices with the SEC between 2012 and 2013. The latest, on August 16, 2013, reports $2.5 million sold of a $3.6 million offering to 10 investors.
Find out what ALLOZYNE INC does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 1600 FAIRVIEW AVE EAST, SUITE 300, Seattle, WA, 98102
- Phone
- (206) 957-7300
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506
- SEC identifier (CIK)
- 1345630
The full lists. Form D filings in Washington: 1,095 rows, $54.75, or the new rows each week for $19 a month. Form D filings in Biotechnology: 1,568 rows, $78.40, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, year incorporated, street, city, state and 5 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Aug 16, 2013 | Amendment | $3,553,550 | $2,452,450 | $1,101,100 | 10 | Mar 22, 2013 | sec.gov |
| Apr 5, 2013 | New notice | $1,800,000 | $900,000 | $900,000 | 10 | Mar 22, 2013 | sec.gov |
| Jun 1, 2012 | New notice | $2,002,000 | $2,002,000 | $0 | 5 | May 25, 2012 | sec.gov |
| May 18, 2012 | New notice | $300,000 | $0 | $300,000 | 11 | May 10, 2012 | sec.gov |
| Feb 3, 2012 | New notice | $4,004,000 | $2,502,500 | $1,501,500 | 5 | Jan 25, 2012 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Meenu Chhabra | Executive Officer, Director | |
| Michael Steinmetz | Director | |
| Carl Weissman | Director | |
| David Tirrell | Director | |
| Kenneth Grabstein | Executive Officer | |
| Steven Gillis | Director |
Other biotechnology companies in Washington that filed recently
- Key Proteo, Inc. $2.3 million · Oct 23, 2026
- Inmedix, Inc. $4 million · Oct 22, 2026
- Q-Immune, Inc. $25,000 · Sep 28, 2026
- Hexamer Therapeutics, Inc $500,000 · Sep 15, 2026
- MalarVx, Inc. $125,000 · Aug 25, 2026
- Strella Biotechnology, Inc. $1.8 million · Aug 14, 2026
Every Form D from the week of Aug 12, 2013 · All recent filings in Washington · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what ALLOZYNE INC reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.